# Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

> **NCT07166263** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Base Therapeutics (Shanghai) Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Gastric Cancer (GC)
- Colorectal Cancer

## Interventions

- **DRUG:** NK510
- **DRUG:** NK510

## Key facts

- **NCT ID:** NCT07166263
- **Lead sponsor:** Base Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07166263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07166263, "Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07166263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*